Fondaparinux API

Name	Fondaparinux
Chinese name	磺达肝癸钠
Cas Number	114870-03-0
Source	India
Qualifications	USDMF/-/-/-/-

Fondaparinux is a highly selective factor Xa inhibitor developed by Sanofi and then transferred to GlaxoSmithKline (GSK). It was listed in Europe in 2001 and the United States in 2002. Fondaparinux It is an analog of low molecular weight heparin's active part of heparin anticoagulation characteristic pentose fragment, which can reversibly bind to antithrombin (AT), increase the activity of AT to inhibit Xa by 300 times, thereby effectively inhibiting the coagulation cascade reaction. Unlike enoxaparin, fondaparinux does not bind to platelets and does not affect platelet function and its aggregation and prothrombin time. These are the reasons for the risk of bleeding with enoxaparin; even at very high drug concentrations , Fondaparinux will not activate platelets, and the risk of bleeding is reduced by 50% compared to enoxaparin. Since Fondaparinux Sodium does not have the negative effect of thrombocytopenia caused by purity of other heparin products, it does not need to be monitored during use, is convenient to use, and has a bioavailability of 100% and a half-life of more than 17 hours, making it the preferred pillar of heparin products product.

Hot Tags: fondaparinux api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Tippyridine Hydrochloride API, Vardenafil API, Idebenone API, Cinacalcet Hydrochloride API, Lifitegrast API, Teriflunomide API

• Previous: Letrozole API
• Next: Salmeterol Xinafoate API